Malik Fady Ibraham

Exercising 3,500 option shares at a low $7.80 strike price every two weeks and immediately selling them at market prices near $80 to $86 per share exemplifies Fady Ibraham Malik's systematic monetization program at Cytokinetics Inc (CYTK). Malik executed this exact 3,500-share exercise-and-sell block three times in mid-2026: on July 21 at $80.59 per share ($282,065 proceeds), on July 7 at $86.62 per share ($303,170 proceeds), and on June 23 at $79.51 per share ($278,285 proceeds). Across 368 Cytokinetics Form 4 filings, Malik's cumulative sales reach 811,663 shares with zero open-market purchases.